The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy

Drug Resistance Updates

Volumn 6, Issue 1, 2003, Pages 15-26

  Grant, Steven ^a   Roberts, John D ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Combination therapy; Cyclins; Flavopiridol; UCN 01

Indexed keywords

4 N ACETYLDINALINE; 7 HYDROXYSTAUROSPORINE; ANTISENSE OLIGONUCLEOTIDE; APICIDIN; ARYLBUTYRIC ACID DERIVATIVE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; BUTYRIC ACID; BUTYROLACTONE; CGP 74514A; COLECALCIFEROL; CPG 74514A; CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOTOXIC AGENT; DEPSIPEPTIDE; FLAVOPIRIDOL; GELDANAMYCIN; LACTACYSTIN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OLOMOUCINE; PAULLONE DERIVATIVE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEASOME INHIBITOR; PURINE DERIVATIVE; RETINOIC ACID; ROSCOVITINE; STAUROSPORINE; SU 9516; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW;

EID: 0037302850     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(02)00141-3     Document Type: Review

References (134)

1. Achenbach, T.V., Muller, R., Slater, E.P., 2000. Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release. J. Biol. Chem. 275, 32089-32097.
2. Ackland, S.P., Schilsky, R.L., 1987. High-dose methotrexate: a critical reappraisal. J. Clin. Oncol. 5, 2017-2031.
3. Adams, J.M., Cory, S., 2001. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem. Sci. 26, 61-66.
4. Akinaga, S., Gomi, K., Morimoto, M., Tamaoki, T., Okabe, M., 1991. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res. 51, 4888-4892.
5. Akinaga, S., Nomura, K., Gomi, K., Okabe, M., 1993. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother. Pharmacol. 32, 183-189.
6. Akiyama, T., Yoshida, T., Tsujita, T., Shimizu, M., Mizukami, T., Okabe, M., Akinaga, S., 1997. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res. 57, 1495-1501.
7. Alessi, F., Quarta, S., Savio, M., Riva, E, Rossi, L., Stivala, L.A., Scovassi, A.I., Meijer, L., Prosperi, E., 1998. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Exp. Cell Res. 245, 8-18.
8. Archer, S.Y., Meng, S., Shei, A., Hodin, R.A., 1998. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. U.S.A. 95, 6791-6796.
9. Arguello, F., Alexander, M., Sterry, J.A., Tudor, G., Smith, E.M., Kalavar, N.T., Greene, Jr., J.F., et al., 1998. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91, 2482-2490.
10. Asada, M., Yamada, T., Ichijo, H., Delia, D., Miyazono, K., Fukumuro, K., Mizutani, S., 1999. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation, EMBO J. 18, 1223-1234.
11. Baer, M.R., George, S.L., Dodge, R.K., O'Loughlin, K.L., Minderman, H., Caligiuri, M.A., et al., 2002. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100, 1224-1232.
12. Bertrand, R., Solary, E., O'Connor, P., Kohn, K.W., Pommier, Y., 1994. Induction of a common pathway of apoptosis by staurosporine. Exp. Cell Res. 211, 314-321.
13. Bible, K.C., Kaufmann, S.H., 1996. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res. 56, 4856-4861.
14. Bible, K.C., Kaufmann, S.H., 1997. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res. 57, 3375-3380.
15. Bible, K.C., Lensing, J.L., Nelson, S.A., Daiss, M.K., Lee, Y.K., Rubin, J., Kaufmann, S.H., Erlichman, C., 2002. A phase 1 trial of flavopiridol combined with cisplatin in patients with advanced malignancies. Proc. Am. Assoc. Cancer Res. 43, 553 (abstract 2749).
16. Bunch, R.T., Eastman, A., 1996. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin. Cancer Res. 2, 791-797.
17. Buquet-Fagot, C., Lallemand, F., Montagne, M.N., Mester, J., 1997. Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines. Anticancer Drugs 8, 623-631.
18. Busby, E.C., Leistritz, D.F., Abraham, R.T., Karnitz, L.M., Sarkaria, J.N., 2000. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res. 60, 2108-2112.
19. Byrd, J.C., Shinn, C., Waselenko, J.K., Fuchs, E.J., Lehman, T.A., Nguyen, P.L., et al., 1998. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 92, 3804-3816.
20. Campos, L., Rouault, J.P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., et al., 1993. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81, 3091-3096.
21. Capdeville, R., Buchdunger, E., Zimmermann, J., Matter, A., 2002. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Natl. Rev. Drug Discov. 1, 493-502.
22. Carlson, B.A., Dubay, M.M., Sausville, E.A., Brizuela, L., Worland, P.J., 1996. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 56, 2973-2978.
23. Carlson, B., Lahusen, T., Singh, S., Loaiza-Perez, A., Worland, P.J., Pestell, R., et al., 1999. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 59, 4634-4641.
24. Cartee, L., Wang, Z., Decker, R.H., Chellappan, S.P., Fusaro, G., Hirsch, K.G., Sankala, H.M., Dent, P., Grant, S., 2001. The cyclin-dependent kinase inhibitor (CDK1) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDK1 expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Res. 61, 2583-2591.
25. Chao, S.H., Fujinaga, K., Marion, J.E., Taube, R., Sausville, E.A., Senderowicz, A.M., Peterlin, B.M., Price, D.H., 2000. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275, 28345-28348.
26. Cheng, J.Q., Jiang, X., Fraser, M., Li, M., Dan, H.C., Sun, M., Tsang, B.K., 2002. Role of X-linked inhibitor of apoptosis in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist. Updates 5, 131-146.
27. Connors, J.M., Kouroukis, C., Belch, A., et al., 2001. Flavopiridol for mantle cell lymphoma: moderate activity and frequent disease stabilization. Blood 98, 807a (abstract 3355).
28. Coppock, D.L., Buffolino, P., Kopman, C., Nathanson, L., 1995. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity. Exp. Cell Res. 221, 92-102.
29. Cory, S., Adams, J.M., 2002. The Bcl2 family: regulators of the cellular life-or-death switch. Natl. Rev. Cancer 2, 647-656.
30. Dai, Y., Yu, C., Singh, V., Tang, L., Wang, Z., McInistry, R., Dent, P., Grant, S., 2001. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 61, 5106-5115.
31. Dai, Y., Landowski, T.H., Rosen, S.T., Dent, P., Grant, S., 2002. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood 100, 3333-3343.
32. Dai, Y., Dent, P., Grant, S., 2002. Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514A. Cell Cycle 1, 143-152.
33. Dalton, W.S., 1999. The tumor microenvironment as a determinant of drug response and resistance. Drug Resist. Updates 2, 285-288.
34. Daugas, E., Nochy, D., Ravagnan, L., Loeffler, M., Susin, S.A., Zamzami, N., Kroemer, G., 2000. Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett. 476, 118-123.
35. Davies, T., Pratt, D., Endicott, J., Johnson, L., Noble, M., 2002. Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol. Ther. 93, 125.
36. De Azevedo, Jr., W.F., Mueller-Dieckmann, H.J., Schulze-Gahmen, U., Worland, P.J., Sausville, E., Kim, S.H., 1996. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. U.S.A. 93, 2735-2740.
37. De Azevedo, W.F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M., Kim, S.H., 1997. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243, 518-526.
38. De Azevedo, Jr., W.F., Canduri, F., da Silveira, N.J., 2002. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem. Biophys. Res. Commun. 293, 566-571.
39. De Azevedo, W.F., Tadeu Gaspar, R., Canduri, F., Carlos Camera, J., Freitas da Silveira, J.N., 2002. Molecular model of cyclin-dependent kinase 5 complexed with roscovitine. Biochem. Biophys. Res. Commun. 297, 1154.
40. Decker, R.H., Dai, Y., Grant, S., 2001. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death. Differ. 8, 715-724.
41. Drees, M., Dengler, W.A., Roth, T., Labonte, H., Mayo, J., Malspeis, L., Grever, M., Sausville, E.A., Fiebig, H.H., 1997. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin. Cancer Res. 3, 273-279.
42. Fuse, E., Tanii, H., Kurata, N., Kobayashi, H., Shimada, Y., Tamura, T., et al., 1998. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res. 58, 3248-3253.
43. Gojo, I., Zhang, B., Fenton, R.G., 2002. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin. Cancer Res. 8, 3527-3538.
44. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., Sawyers, C.L., 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880.
45. Graves, P.R., Yu, L., Schwarz, J.K., Gales, J., Sausville, E.A., O'Connor, P.M., Piwnica-Worms, H., 2000. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 275, 5600-5605.
46. Gries, J.-M., Kasimis, B., Schwarzenberger, P., Shapiro, G., Fidias, P., Rodrigues, L., Cogswell, J., Bukowski, R.M., 2002. Phase I study of HMR1275 (flavopiridol) in non-small cell lung cancer (NSCLC) patients after a 24 h IV administration in combination with paclitaxel and carboplatin. Proc. Am. Soc. Clin. Oncol. 21, 94a (abstract 373).
47. Gudas, J., Nguyen, H., Li, T., Hill, D., Cowan, K.H., 1995. Effects of cell cycle, wild-type p53 and DNA damage on p21CIP1/Waf1 expression in human breast epithelial cells. Oncogene 11, 253-261.
48. Harvey, S., Decker, R., Dai, Y., Schaefer, G., Tang, L., Kramer, L., Dent, P., Grant, S., 2001. Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells. Clin. Cancer Res. 7, 320-330.
49. Hatakeyama, M., Weinberg, R.A., 1995. The role of RB in cell cycle control. Prog. Cell Cycle Res. 1, 9-19.
50. Hsueh, C.T., Kelsen, D., Schwartz, G.K., 1998. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracilinduced apoptosis in a sequence-dependent manner. Clin. Cancer Res. 4, 2201-2206.
51. Igney, F.H., Krammer, P.H., 2002. Death and anti-death: tumour resistance to apoptosis. Natl. Rev. Cancer. 2, 277-288.
52. Joza, N., Kroemer, G., Penninger, J.M., 2002. Genetic analysis of the mammalian cell death machinery. Trends Genet. 18, 142-149.
53. Kaelin, Jr., W.G., 1999. Functions of the retinoblastoma protein. Bioessays 21, 950-958.
54. Karp, J.E., Yang, W.D., Tidwell, M., Greer, J., Wei, M., Guo, C., Ross, D.D., 2001. Timed sequential therapy (TST) of acute leukemia with flavopiridol (FP): in vitro model for a phase I clinical trial. Blood 98, 2487 (abstract).
55. Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., Sausville, E., 1992. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst. 84, 1736-1740.
56. Kelland, L.R., 2000. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin. Investig. Drugs 9, 2903-2911.
57. King, K.L., Cidlowski, J.A., 1995. Cell cycle and apoptosis: common pathways to life and death. J. Cell. Biochem. 58, 175-180.
58. Kitada, S., Zapata, J.M., Andreeff, M., Reed, J.C., 2000. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96, 393-397.
59. Kitagawa, M., Higashi, H., Takahashi, I.S., Okabe, T., Ogino, H., Taya, Y., Hishimura, S., Okuyama, A., 1994. A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression. Oncogene 9, 2549-2557.
60. Kreis, W., Budman, D.R., Chan, K., Allen, S.L., Schulman, P., Lichtman, S., Weiselberg, L., Schuster, M., Freeman, J., Akerman, S., 1988. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over 3 h. Cancer Res. 48, 1337-1342.
61. Krystal, G.W., 2001. Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents. Drug Resist. Updates 4, 16-21.
62. Lane, M.E., Yu, B., Rice, A., Lipson, K.E., Liang, C., Sun, L., Tang, C., McMahon, G., Pestell, R.G., Wadler, S., 2001. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 61, 6170-6177.
63. Lee, M.H., Yang, H.Y., 2001. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol. Life Sci. 58, 1907-1922.
64. Legraverend, M., Ludwig, O., Bisagni, E., Leclerc, S., Meijer, L., Giocanti, N., Sadri, R., Favaudon, V., 1999. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. 7, 1281-1293.
65. Leost, M., Schultz, C., Link, A., Wu, Y.Z., Biernat, J., Mandelkow, E.M., et al., 2000. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 267, 5983-5994.
66. Losiewicz, M.D., Carlson, B.A., Kaur, G., Sausville, E.A., Worland, P.J., 1994. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. 201, 589-595.
67. Lu, Y., Yamagishi, N., Yagi, T., Takebe, H., 1998. Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells. Oncogene 16, 705-712.
68. Mani, S., Wang, C., Wu, K., Francis, R., Pestell, R., 2000. Cyclin-dependent kinase inhibitors: novel anticancer agents. Expert Opin. Investig. Drugs 9, 1849-1870.
69. Matranga, C.B., Shapiro, G.I., 2002. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res. 62, 1707-1717.
70. Kip1: a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line. Oncogene 16, 3337-3343.
71. McClue, S.J., Blake, D., Clarke, R., Cowan, A., Cummings, L., Fischer, P.M., et al., 2002. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 102, 463-468.
72. McKinstry, R., Qiao, L., Yacoub, A., Dai, Y., Decker, R., Holt, S., et al., 2002. Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells. Cancer Biol. Ther. 1, 243-253.
73. Meijer, L., 2000. Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents. Drug Resist. Updates 3, 83-88.
74. Mizuno, K., Noda, K., Ueda, Y., Hanaki, H., Saido, T.C., Ikuta, T., et al., 1995. UCN-01, an anti-tumor drug, is a selective inhibitor of the conventional PKC subfamily. FEBS Lett. 359, 259-261.
75. Morgan, D.O., 1995. Principles of CDK regulation. Nature 374, 131-134.
76. Morgan, D.O., 1997. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 13, 261-291.
77. Motwani, M., Delohery, T.M., Schwartz, G.K., 1999. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res. 5, 1876-1883.
78. Motwani, M., Li, X., Schwartz, G.K., 2000. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells. Clin. Cancer Res. 6, 924-932.
79. Motwani, M., Jung, C., Sirotnak, F.M., She, Y., Shah, M.A., Gonen, M., Schwartz, G.K., 2001. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in HCT116 colon cancer monolayers and xenografts. Clin. Cancer Res. 7, 4209-4219.
80. Nishio, K., Ishida, T., Arioka, H., Kurokawa, H., Fukuoka, K., Nomoto, T., et al., 1996. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. Anticancer Res. 16, 3387-3395.
81. Niu, M.Y., Menard, M., Reed, J.C., Krajewski, S., Pratt, M.A., 2001. Ectopic expression of cyclin D1 amplifies a retinoic acid-induced mitochondrial death pathway in breast cancer cells. Oncogene 20, 3506-3518.
82. Nurse, P., 2000. A long twentieth century of the cell cycle and beyond. Cell 100, 71-78.
83. Obaya, A.J., Sedivy, J.M., 2002. Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol. Life Sci. 59, 126-142.
84. Parker, B.W., Kaur, G., Nieves-Neira, W., Taimi, M., Kohlhagen, G., Shimizu, T., et al., 1998. Senderowicz early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91, 458-465.
85. Patel, V., Senderowicz, A.M., Pinto, Jr., D., Igishi, T., Raffeld, M., Quintanilla-Martinez, L., et al., 1998. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Invest. 102, 1674-1681.
86. Qin, X.Q., Livingston, D.M., Kaelin, Jr., W.G., Adams, P.D., 1994. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. U.S.A. 91, 10918-10922.
87. Rahmani, M., Grant, S., 2002. UCN-01 (7-hydroxystauorsporine) blocks PMA-induced maturation and reciprocally promotes apoptosis in human myelomonocytic leukemia cells (U937). Cell Cycle 1, 273-281.
88. Ravagnan, L., Roumier, T., Kroemer, G., 2002. Mitochondria, the killer organelles and their weapons. J. Cell. Physiol. 192, 131-137.
89. Richon, V.M., Sandhoff, T.W., Rifkind, R.A., Marks, P.A., 2000. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U.S.A. 97, 10014-10019.
90. CIP1 expression and maturation while enhancing apoptosis in human myeloid leukemia cells. Mol. Cancer Therap. 1, 253-266.
91. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., et al., 1999. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. U.S.A. 96, 4592-4597.
92. Sampath, D., Shi, Z., Plunkett, W., 2002. Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine. Mol. Pharmacol. 62, 680-688.
93. Sasaki, Y., Sasaki, T., Minami, H., Kawada, K., Fujii, H., Igarashi, T., et al., 2002. A phase I pharmacokinetic (PK)-pharmacodynamic (PD) study of flavopiridol by 24 h continuous infusion (CI) repeating every week. Proc. Am. Soc. Clin. Oncol. 21, 93a (abstract 371).
94. Sato, S., Fujita, N., Tsuruo, T., 2002. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21, 1727-1738.
95. Sausville, E.A., Lush, R.D., Headlee, D., Smith, A.C., Figg, W.D., Arbuck, S.G., et al., 1998. Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer Chemother. Pharmacol. 42 (Suppl.), S54-S59.
96. Sausville, E.A., Johnson, J., Alley, M., Zaharevitz, D., Senderowicz, A.M., 2000. Inhibition of CDKs as a therapeutic modality. Ann. N. Y. Acad. Sci. 910, 207-221.
97. Sausville, E.A., Arbuck, S.G., Messmann, R., Headlee, D., Bauer, K.S., Lush, R.M., et al., 2001. Phase I trial of 72-h continuous infusion UCN-01 in patients with refractory neoplasms. J. Clin. Oncol. 19, 2319-2333.
98. Schultz, C., Link, A., Leost, M., Zaharevitz, D.W., Gussio, R., Sausville, E.A., et al., 1999. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem. 42, 2909-2919.
99. Schwartz, G.K., Kaubisch, A., Saltz, L., Ilson, D., O'Reilly, E., Barazzuol, J., et al., 1999. Phase I trial of sequential paclitaxel and cisplatin in combination with the cyclin dependent kinase inhibitor flavopiridol in patients with advanced solid tumors. Proc. AACR-NCI-EORTC, 26 (abstract 122).
100. Schwartz, G.K., Ilson, D., Saltz, L., O'Reilly, E., Tong, W., Maslak, P., et al., 2001. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J. Clin. Oncol. 19, 1985-1992.
101. Schwartz, G.K., O'Reilly, E., Ilson, D., Saltz, L., Sharma, S., Tong, W., et al., 2002. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J. Clin. Oncol. 20, 2157-2170.
102. Sedlacek, H.H., Czech, J., Naik, R., et al, 1996. Flavopiridol (L86-8275, NSC-649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol. 9, 1143-1168.
103. Sedlacek, H.H., 2001. Mechanisms of action of flavopiridol. Crit. Rev. Oncol. Hematol. 38, 139-170.
104. Senderowicz, A.M., Headlee, D., Stinson, S.F., Lush, R.M., Kalil, N., et al., 1998. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol. 16, 2986-2999.
105. Senderowicz, A.M., 2001. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy. Cancer Chemother. Biol. Response Modif. 19, 165-188.
106. Seynaeve, C.M., Stetler-Stevenson, M., Sebers, S., Kaur, G., Sausville, E.A., Worland, P.J., 1993. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res. 53, 2081-2086.
107. Shah, M.A., Schwartz, G.K., 2000. The relevance of drug sequence in combination chemotherapy. Drug Resist. Updates 3, 335-356.
108. Shah, M.A., Kortmansky, J., Gonen, M., O'Reilly, E., Sharma, S., Saltz, L.B., et al., 2002. A phase I/pharmacologic study of weekly sequential irinotecan (CPT) and flavopiridol (F). Proc. Am. Soc. Clin. Oncol. 21, 94a (abstract 373).
109. Shah, N., Nicoll, J., Nagar, B., Gorre, M., Paquette, R., Kuriyan, J., Sawyers, C., 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117.
110. Shapiro, G.I., Koestner, D.A., Matranga, C.B., Rollins, B.J., 1998. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin. Cancer Res. 5, 2925-2938.
111. Shapiro, G.I., Supko, J.G., Patterson, A., Lynch, C., Lucca, J., Zacarola, P.F., et al., 2001. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin. Cancer Res. 7, 1590-1599.
112. Sherr, C.J., 2001. Cell cycle control and cancer. Harvey Lect. 96, 73-92.
113. Sherr, C.J., 2000. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60, 3689-3695.
114. Shi, Z., Azuma, A., Sampath, D., Li, Y.X., Huang, P., Plunkett, W., 2001. S-phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res. 61, 1065-1072.
115. Srinivasula, S.M., Hegde, R., Saleh, A., Datta, P., Shiozaki, E., Chai, J., et al., 2001. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410, 112-116.
116. Kip1 on resistance of tumor cells to anticancer agents. Nat. Med. 2, 1204-1210.
117. Stadler, W.M., Vogelzang, N.J., Amato, R., Sosman, J., Taber, D., Liebowitz, D., Vokes, E.E., 2000. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J. Clin. Oncol. 18, 371-375.
118. Sun, X.M., MacFarlane, M., Zhuang, J., Wolf, B.B., Green, D.R., Cohen, G.M., 1999. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J. Biol. Chem. 274, 5053-5060.
119. Suzuki, M., Hosaka, Y., Matsushima, H., Goto, T., Kitamura, T., Kawabe, K., 1999. Butyrolactone I induces cyclin B1 and causes G2/M arrest and skipping of mitosis in human prostate cell lines. Cancer Lett. 138, 121-130.
120. Tan, A.R., Headlee, D., Messmann, R., Sausville, E.A., Arbuck, S.G., Murgo, A.J., et al., 2002a. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-h infusion in patients with advanced neoplasms. J. Clin. Oncol. 20, 4074-4082.
121. Tan, A.R., Zhai, S., Berman, A.S., Figg, W.D., Yang, X., Swain, S.M., 2002b. Phase I trial of docetaxel followed by infusional flavopiridol over 72h in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 21, 36b (abstract 1955).
122. Tang, L., Boise, L.H., Dent, P., Grant, S., 2000. Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01). Biochem. Pharmacol. 60, 1445-1456.
123. Wadler, S., 2001. Perspectives for cancer therapies with cdk2 inhibitors. Drug Resist. Updates 4, 347-367.
124. Walczak, H., Krammer, P.H., 2000. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 256, 58-66.
125. Wang, J., Walsh, K., 1996. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 273, 359-361.
126. Wang, J.L., Liu, D., Zhang, Z.J., Shan, S., Han, X., Srinivasula, S.M., Croce, C.M., Alnemri, E.S., Huang, Z., 2000. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. U.S.A. 97, 7124-7129.
127. Wang, Q., Worland, P.J., Clark, J.L., Carlson, B.A., Sausville, E.A., 1995. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ. 6, 927-936.
128. Wang, S., Vrana, J.A., Bartimole, T.M., Freemerman, A.J., Jarvis, W.D., Kramer, L.B., Krystal, G., Dent, P., Grant, S., 1997. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Mol. Pharmacol. 52, 1000-1009.
129. Winters, Z.E., Ongkeko, W.M., Harris, A.L., Norbury, C.J., 1998. p53 regulates Cdc2 independently of inhibitory phosphorylation to reinforce radiation-induced G2 arrest in human cells. Oncogene 17, 673-684.
130. Yu, B., Lane, M.E., Wadler, S., 2002. SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. Biochem. Pharmacol. 64, 1091-1100.
131. Yu, C., Krystal, G., Dent, P., Grant, S., 2002. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in Bcr-Abl-positive human leukemia cells. Clin. Cancer Res. 8, 2976-2984.
132. Zaffaroni, N., Daidone, M.G., 2002. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist. Updates 5, 65-72.
133. Zaharevitz, D.W., Gussio, R., Leost, M., Senderowicz, A.M., Lahusen, T., Kunick, C., Meijer, L., Sausville, E.A., 1999. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 59, 2566-2569.
134. Zou, H., Li, Y., Liu, X., Wang, X., 1999. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274, 11549-11556.